Reponex Pharmaceuticals A/S

Reponex Pharmaceuticals Prioritizes Clinical Programs for Colon Cancer, Peritonitis, and IBD

- Reponex Pharmaceuticals prioritizes RNX-051 for colon adenomas and colon cancer, RNX-011 for peritonitis, and RNX-041 for IBD (pouchitis) due to strong clinical data. - Phase 2 clinical trial applications for RNX-011 and RNX-051 are expected to be submitted to regulatory authorities in early and late Q1 2025, respectively. - Reponex will use patient blood samples to confirm RNX-011's mechanism in peritonitis, aiming to individualize treatment and support clinical studies. - Proof-of-concept study data for RNX-021 in chronic venous leg ulcers informs formulation work for RNX-022 and RNX-023, pursued via strategic collaborations.